Drug
Rta 402 Dose1
Rta 402 Dose1: highest development phase Phase 2, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| RTA 402 Dose1 NCT00535314 | Phase 2 | Malignant Melanoma |
Latest
No recent events.
Follow Rta 402 Dose1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.